pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

967 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT776Endpoints579BioPharma Dive223onclive165Fierce Biotech54BioSpace52raps22
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology6
  • Cayman court says Apple Tree general partner should lose control of venture fund
    The embattled venture firm Apple Tree Partners has suffered a loss in a Cayman Islands court case against its main limited partner. A judge in the Grand Court of the Cayman Islands ruled on Frida…
    Endpoints · 11d ago↗ source
  • FDA finalizes guidance on psychedelics, plans broader hearing
    The FDA has finalized clinical guidance for psychedelic drug developers and has scheduled a public hearing on future therapeutic use, adding regulatory momentum to a class on the precipice of appro…
    Endpoints · 11d ago↗ source
  • Freenome colorectal cancer test data improve on earlier results
    <figure><div><img src="https://imgproxy.divecdn.com/t2eSQFnULTRPQ6pHoF74ilRTdrAlEvvFROsITsihAlw/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMDUzMDQ1NTczLmpwZ…
← prev
page 6 of 39
next →
Hematology6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
BioPharma Dive · 11d ago
↗ source
  • FDA proposes rule to simplify drugmakers' factory registrations
    The FDA is proposing a rule to change how factories are registered with the agency if they are making products for the US market, as part of a continuing effort to try to speed up ...
    Endpoints · 11d ago↗ source
  • Q32 bounces back to claim study success for alopecia drug
    <figure><div><img src="https://imgproxy.divecdn.com/_dT9zKJsCoS0jrFraV8Vdkcut5aCVtKPN0y1PuLlKnE/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMTUwMzE2NTA1LmpwZ…
    BioPharma Dive · 11d ago↗ source
  • Health tech funding rises to $7.4B in the first half of 2026
    Digital health startups raised $7.4 billion in venture funding during the first half of 2026, up $1 billion from the first half of 2025, according to research and venture firm Rock Health. Megaro…
    Endpoints · 11d ago↗ source
  • Agenus surges on study pivot; Apnimed lines up an IPO
    <figure><div><img src="https://imgproxy.divecdn.com/idsdMAHsPbXObDUtQW2qRG7uveBUVv6HCTn9NTtlDOI/g:nowe:0:0/c:1207:682/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0x…
    BioPharma Dive · 11d ago↗ source
  • Busy M&A activity sets tone as biopharma earnings season kicks off
    With the first half of 2026 officially in the books and another earnings season about to begin, a key question hangs over the biopharma industry: Will the good times continue? The answer to that…
    Endpoints · 11d ago↗ source
  • Tris Pharma's CRL for narcolepsy drug; Agenus abandons Phase 3 CRC trial
    Plus, news about Insilico, Ipsen, Q32 Bio, GSK’s Jemperli, Drug Farm and Padcev. ❌ FDA rejects Tris Pharma’s narcolepsy drug: Its rejection letter said that “additional information will be necess…
    Endpoints · 11d ago↗ source
  • Biotech startup funding gap widens despite rebound in VC investment
    <figure><div><img src="https://imgproxy.divecdn.com/P3H5TGon7uXjRD49-L7jbsm0pv5Sbvx3i-CT1yYEXeg/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMTM5MDkwNTYwX0lGd…
    BioPharma Dive · 11d ago↗ source
  • Deals, deals, deals; Biohaven takes on Eli Lilly; and more
    Welcome back to Endpoints Weekly! Don’t miss Ryan Cross’ deep dive into the paranoia caused by competition with China. Ryan writes that US biotech companies are holding their cards close to the ...
    Endpoints · 13d ago↗ source
  • Apnimed files for IPO as FDA reviews its sleep apnea drug
    Apnimed is finally going forward with an IPO attempt after years of flirting with the milestone. The Cambridge, MA-based biotech revealed its Nasdaq plans on Friday night, following a strong six ...
    Endpoints · 14d ago↗ source
  • FDA returns to releasing pharma rejection letters with 14 new CRLs
    The FDA on Friday posted 14 new rejection letters to pharma companies online, days after HHS confirmed to Endpoints News that the agency had paused new CRL releases because of a pharma-backed ...
    Endpoints · 14d ago↗ source
  • FDA rejects Hengrui-Elevar liver cancer drug combo for third time
    For the third time in about two years, the FDA has cited manufacturing deficiencies in rejecting a drug combination from Jiangsu Hengrui Pharmaceuticals and Elevar Therapeutics intended to treat th…
    Endpoints · 14d ago↗ source
  • CDER adds 100+ new employees in a quarter for first time since late 2024
    The FDA's drug center hired more new employees than it lost in a quarter for the first time since the Trump administration gutted the agency's ranks in April 2025. The FDA's
    Endpoints · 14d ago↗ source
  • US biotechs turn secretive as they fear competition from rising Chinese industry
    Janine Sengstack believes she may have found the next big breakthrough in diabetes and obesity. Her company, Junevity, has searched through hundreds of genes to discover ones that, when repressed,…
    Endpoints · 14d ago↗ source
  • GSK, Hansoh ADC extends survival in lung cancer study
    <figure><div><img src="https://imgproxy.divecdn.com/mDk-h3NLB8udDPFuDlI7IPou1i9tJKJYucQXUnhK9vA/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMTc3MzEzMjc4LmpwZ…
    BioPharma Dive · 14d ago↗ source
  • German lawmakers pass cost-saving bill that drugmakers say will drive them out
    Germany’s federal parliament has voted to pass a bill designed to cut domestic healthcare spending that could negatively impact drugmakers, drawing sharp criticism from the country’s main pharmaceu…
    Endpoints · 14d ago↗ source
  • Hansoh meets Phase 3 SCLC goal; FDA approves Sanofi on-body injector
    Plus, news about Huntington's, Fate Therapeutics and Bausch + Lomb. 🇨🇳 Hansoh touts Phase 3 success for GSK-partnered ADC: The program, called risvutatug rezetecan or Ris-Rez, met its primary e…
    Endpoints · 14d ago↗ source
  • ARPA-H puts $160M into bespoke drug therapies; Biohaven switches up scientific leadership
    <figure><div><img src="https://imgproxy.divecdn.com/idsdMAHsPbXObDUtQW2qRG7uveBUVv6HCTn9NTtlDOI/g:nowe:0:0/c:1207:682/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0x…
    BioPharma Dive · 14d ago↗ source
  • The data that led Cellular Intelligence to pick up Novo's Parkinson's stem cell therapy
    MONTREAL — After Novo Nordisk closed its cell therapy unit, Cellular Intelligence contracted neurologist and drug developer Nuno Mendonça to conduct due diligence on the Danish pharma’s Parkinson’s…
    Endpoints · 14d ago↗ source
  • Pfizer appoints obesity discovery head; AI startup Xaira makes leadership adjustments
    → Danna Breen has been promoted to head of obesity discovery at Pfizer, according to a LinkedIn post. Breen succeeds Kendra Bence and gets this opportunity after nearly 14 years with ...
    Endpoints · 14d ago↗ source
  • Roche scraps two Ionis-partnered Huntington’s drugs
    <p>The Swiss pharmaceutical giant told patient groups tominersen didn't delay disease progression in one trial, while a study of a second drug was scrapped because of a safety signal in animal…
    BioPharma Dive · 15d ago↗ source
  • ARPA-H bookmarks $160M for custom gene editing treatments. Is it enough?
    After an infant last year was saved from a deadly disease thanks to a bespoke gene editing therapy that fixed an incredibly rare mutation in his DNA, the US government is hoping ...
    Endpoints · 15d ago↗ source
  • HHS advances plan to pay out Covid-19 vaccine injury claims
    A newly proposed HHS rule would establish a compensation mechanism for people who claim they were injured by Covid-19 vaccines, as a key panel that oversees broader vaccine injury payments remains…
    Endpoints · 15d ago↗ source